ArticleBlood advances2022
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study.
Open access · goldAbstract read
In one paragraph
Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 61 citations in OpenAlex.
- High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohort.Annals of hematology · 2026Article
- Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).Hematological oncology · 2026Observational
- When, which and how to switch: Navigating JAK inhibitors in myelofibrosis.British journal of haematology · 2026Review
- Health Care Utilization Databases obtained from health system inform outcome for ruxolitinib treatment in patients with myelofibrosis.HemaSphere · 2026Article
- [External validation and incremental value assessment of the RR6 prognostic model in Chinese myelofibrosis patients treated with ruxolitinib: focusing on overall survival].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged 65 Years and Above With Myelofibrosis.Clinical lymphoma, myeloma & leukemia · 2026Article
- Increased Rate of Anemia and Discontinuation in Older Patients with Myelofibrosis Treated with Ruxolitinib.Journal of clinical medicine · 2025Article
- Emerging Therapeutic Approaches for Anemia in Myelofibrosis.Current hematologic malignancy reports · 2025Review
- Article
- Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study.Blood advances · 2025Observational
- Survey of Clinical Practice in Chronic Myeloproliferative Neoplasms in Croatia: A Study by the MPN Working Group Party of the Croatian Cooperative Group for Hematologic Diseases (KROHEM).Journal of clinical medicine · 2025Article
- Review
- Prognostic and Predictive Models in Myelofibrosis.Current hematologic malignancy reports · 2024Review
- Management of Patients with Early Myelofibrosis: A Discussion of Best Practices.Current hematologic malignancy reports · 2024Review
- A novel application of XPO1 inhibition for the treatment of myelofibrosis.Blood neoplasia · 2024Review
- Advances in Myelofibrosis Management: New Janus Kinase Inhibitors Beyond Ruxolitinib.Journal of the advanced practitioner in oncology · 2024Article
- Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.Bone marrow transplantation · 2024Observational
- Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM.Future oncology (London, England) · 2024Article
- Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis.Annals of hematology · 2024Article
- Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives.Frontiers in oncology · 2024Review
Corrections and comments
- Commented on by
Authors and funding
19 authors at 7 institutions in 3 countries.
Paola GuglielmelliCenter of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, Florence, University of Florence, Italy.ORCID 0000-0003-1809-284X
Arianna GhirardiFondazione per la Ricerca Ospedale Maggiore (FROM), Papa Giovanni XXIII Hospital, Bergamo, Italy.
Alessandra CarobbioFondazione per la Ricerca Ospedale Maggiore (FROM), Papa Giovanni XXIII Hospital, Bergamo, Italy.ORCID 0000-0001-9664-7084
Arianna MasciulliFondazione per la Ricerca Ospedale Maggiore (FROM), Papa Giovanni XXIII Hospital, Bergamo, Italy.
Chiara MaccariCenter of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, Florence, University of Florence, Italy.
Barbara MoraHematology, Aziende Socio Sanitarie Territoriali (ASST) Sette Laghi, University of Insubria, Varese, Italy.
Elisa RumiDivision of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy.ORCID 0000-0002-7572-9504
Ana TrigueroDepartment of Hematology, Hospital, Clinic de Barcelona, Barcelona, Spain.
Maria Chiara FinazziDepartment of Oncology-Hematology, University of Milan and Papa Giovanni XXIII Hospital, Bergamo, Italy.
Helna PetterssonDivision of Hematology, NU Hospital Group, Uddevalla, Sweden; and.
Chiara PaoliCenter of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
Francesco MannelliCenter of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.ORCID 0000-0003-4810-6501
Daniele VanniDivision of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy.
Alessandro RambaldiDepartment of Oncology-Hematology, University of Milan and Papa Giovanni XXIII Hospital, Bergamo, Italy.
Francesco PassamontiHematology, Aziende Socio Sanitarie Territoriali (ASST) Sette Laghi, University of Insubria, Varese, Italy.
Alberto Alvarez-LarrànDepartment of Hematology, Hospital, Clinic de Barcelona, Barcelona, Spain.
Bjorn AndreassonDivision of Hematology, NU Hospital Group, Uddevalla, Sweden; and.
Alessandro M VannucchiCenter of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, Florence, University of Florence, Italy.ORCID 0000-0001-5755-0730
Tiziano BarbuiFondazione per la Ricerca Ospedale Maggiore (FROM), Papa Giovanni XXIII Hospital, Bergamo, Italy.ORCID 0000-0003-2747-6327
Azienda Ospedaliero-Universitaria Careggi · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITHospital Clínic de Barcelona · ESIstituti di Ricovero e Cura a Carattere Scientifico · ITNU Hospital Group · SEUniversity of Insubria · ITUniversity of Milan · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Primary MyelofibrosisHumansNitrilesPyrazolesPyrimidinesNitrilesPyrazolesPyrimidinesruxolitinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.